폐렴 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 감염 유형별, 유형별, 약제클래스별, 최종사용자별, 지역별, 경쟁별 세분화(2020-2030년)

The Global Pneumonia Therapeutics Market will grow from USD 2.91 Billion in 2024 to USD 4.56 Billion by 2030 at a 7.76% CAGR. Pneumonia therapeutics comprise a class of pharmaceutical interventions and medical treatments aimed at combating pneumonia, a serious respiratory infection characterized by inflammation of the lung's air sacs. The global market's expansion is fundamentally propelled by the persistent high global incidence of respiratory illnesses, particularly among susceptible demographics such as the elderly and young children.

Key Market Drivers

The global pneumonia therapeutics market is significantly driven by the increasing worldwide incidence of pneumonia and the escalating threat of antibiotic resistance. The persistent high global incidence of pneumonia creates a continuous and expanding patient population requiring various therapeutic interventions, from initial antimicrobial treatments to supportive care. This rising burden necessitates robust market supply and fosters demand for improved treatment efficacy and accessibility across diverse demographics.

Key Market Challenges

The substantial financial investment and stringent regulatory approval processes for new broad-spectrum antibiotics and antiviral treatments pose a significant impediment to the growth of the global pneumonia therapeutics market. The lengthy and complex journey from initial research to market entry demands considerable capital, which can deter potential innovators and reduce the incentive for pharmaceutical companies to invest in this critical area. This is particularly relevant for novel agents, where the inherent risk of failure is high, and the return on investment can be uncertain due to evolving pathogen resistance and specific treatment protocols aimed at preserving drug efficacy.

Key Market Trends

The emergence of novel therapeutic classes, such as monoclonal antibodies and host-directed therapies, represents a significant growth trend in the global pneumonia therapeutics market. These innovative treatments move beyond traditional antibiotics, offering new mechanisms to combat infection and address the pressing challenge of antimicrobial resistance. Monoclonal antibodies provide targeted immune responses, while host-directed therapies modulate the body's own defense mechanisms, potentially leading to broader efficacy and reduced development of resistance.

Key Market Players

• Pfizer Inc.
• AstraZeneca Plc.
• Eli Lilly & company
• F. Hoffmann-La Roche Ltd.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited

Report Scope:

In this report, the Global Pneumonia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumonia Therapeutics Market, By Infection Type:

• Hospital-acquired Pneumonia [HAP]
• Community-acquired Pneumonia [CAP]
• Ventilator-associated Pneumonia [VAP]

Pneumonia Therapeutics Market, By Type:

• Drugs
• Preventive Vaccines
• Oxygen Therapy

Pneumonia Therapeutics Market, By Drug Class:

• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

Pneumonia Therapeutics Market, By End User:

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

Pneumonia Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Pneumonia Therapeutics Market.

Available Customizations:

Global Pneumonia Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pneumonia Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP])
  • 5.2.2. By Type (Drugs, Preventive Vaccines, Oxygen Therapy)
  • 5.2.3. By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs)
  • 5.2.4. By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Pneumonia Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Infection Type
  • 6.2.2. By Type
  • 6.2.3. By Drug Class
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pneumonia Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Infection Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Drug Class
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Pneumonia Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Infection Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Drug Class
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Pneumonia Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Infection Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Drug Class
      • 6.3.3.2.4. By End User

7. Europe Pneumonia Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Infection Type
  • 7.2.2. By Type
  • 7.2.3. By Drug Class
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pneumonia Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Infection Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Drug Class
      • 7.3.1.2.4. By End User
  • 7.3.2. France Pneumonia Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Infection Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Drug Class
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Pneumonia Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Infection Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Drug Class
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Pneumonia Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Infection Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Drug Class
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Pneumonia Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Infection Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Drug Class
      • 7.3.5.2.4. By End User

8. Asia Pacific Pneumonia Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Infection Type
  • 8.2.2. By Type
  • 8.2.3. By Drug Class
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pneumonia Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Infection Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Drug Class
      • 8.3.1.2.4. By End User
  • 8.3.2. India Pneumonia Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Infection Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Drug Class
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Pneumonia Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Infection Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Drug Class
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Pneumonia Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Infection Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Drug Class
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Pneumonia Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Infection Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Drug Class
      • 8.3.5.2.4. By End User

9. Middle East & Africa Pneumonia Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Infection Type
  • 9.2.2. By Type
  • 9.2.3. By Drug Class
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pneumonia Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Infection Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Drug Class
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Pneumonia Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Infection Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Drug Class
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Pneumonia Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Infection Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Drug Class
      • 9.3.3.2.4. By End User

10. South America Pneumonia Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Infection Type
  • 10.2.2. By Type
  • 10.2.3. By Drug Class
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pneumonia Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Infection Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Drug Class
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Pneumonia Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Infection Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Drug Class
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Pneumonia Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Infection Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Drug Class
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pneumonia Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca Plc.
• 15.3. Eli Lilly & company
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. Viatris Inc.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Sanofi SA
• 15.8. Novartis AG
• 15.9. Sun Pharmaceutical Industries Ltd.
• 15.10. Aurobindo Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer